BPC-157 to speed healing of acute grade II hamstring strains

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled Phase 2 trial enrolls adults 18–45 with MRI-confirmed acute grade II hamstring strains and randomizes them 1:1 to daily subcutaneous BPC-157 or matching placebo for 14 days alongside a standardized rehabilitation program. Co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14, with clinical assessments at Days 3, 7, 14, 28, 56 and a 3-month post-return follow-up for recurrence monitoring. Safety is tracked through adverse events, vital signs, laboratory tests, and oversight by an independent Data and Safety Monitoring Committee. Preclinical data suggest BPC-157 may promote tissue protection, angiogenesis, and repair, but human evidence in musculoskeletal injuries is limited.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 to 45 years.
* Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening.
* MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion.
* Pre-injury physical activity \>= 3 sessions/week or participation in organized recreational sport.
* Willingness to follow the standardized rehabilitation protocol and attend all study visits.
* For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose.

Exclusion Criteria:

* Grade III hamstring tear, tendon avulsion, or injury requiring surgical management.
* Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment.
* Prior hamstring strain on the index limb within the past 6 months.
* Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days prior to screening.
* Known bleeding disorder or current therapeutic anticoagulation.
* Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk.
* Known allergy or hypersensitivity to components of the investigational product or placebo.
* Pregnant or breastfeeding.
* Current participation in another interventional clinical study or participation within 30 days prior to screening.
* Currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority

Where it's running

• Peking University Shenzhen Hospital
  Shenzhen, Guangdong, China Recruiting

Study contacts

• Study coordinator: Seni S Lu, Phd
• Email: Seni-Lu@beijing-biotech.com
• Phone: +86 13076790030

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Criteria-based vs time-based rehabilitation for football players

  This trial tests whether a criteria-based rehab plan helps football players 18–35 recover faster and safely return to play after hamstring injuries, ACL issues, or ankle sprains, compared with a fixed six-week plan.

  Recruiting at 2 sites Riphah International University · Islamabad, Federal and 1 other locations · NCT07815340

• Acute Effects of Neurodynamics on Hamstrings in Athletes

  This study tests whether neurodynamic techniques can help athletes keep or improve hamstring strength and endurance.

  Recruiting High Point University · High Point, North Carolina · NCT07721220

• MOTS-c to improve insulin sensitivity in adults with prediabetes and overweight or obesity

  This 12-week test will see if the investigational peptide MOTS-c can improve insulin sensitivity in adults with prediabetes who are overweight or have obesity.

  Recruiting Phase 2 Hudson Biotech · Shenzhen, Guangdong · NCT07505745

• TB-500 (thymosin beta 4 fragment) to improve blood vessel function in people with stable atherosclerotic cardiovascular disease

  This trial will test whether TB-500 (a fragment of thymosin beta 4) is safe and can improve blood vessel function in adults aged 40–75 with stable ASCVD.

  Recruiting Phase 1/2 Hudson Biotech · Shenzhen, Guangdong · NCT07487363

• Once-weekly tirzepatide injections for adults with obesity or overweight and weight-related conditions

  This trial will see if once-weekly tirzepatide injections (5 mg, 10 mg, or 15 mg) plus a reduced-calorie diet and increased activity help adults with obesity or overweight (without diabetes) lose and keep off weight compared with placebo.

  Recruiting Phase 3 Hudson Biotech · Shenzhen, Guangdong · NCT07481747

• Tesamorelin to reduce liver fat in adults with fatty liver disease

  This trial tests whether a daily self‑injection of tesamorelin can lower liver fat over 52 weeks in adults with fatty liver disease.

  Recruiting Phase 2 Hudson Biotech · Shenzhen, Guangdong · NCT07481734

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.